Literature DB >> 5101382

Dopa and 3-O-methyldopa in cerebrospinal fluid of Parkinsonism patients during treatment with oral L-dopa.

N S Sharpless, D S McCann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5101382     DOI： 10.1016/0009-8981(71)90373-1

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN： 0009-8981            Impact factor:   3.786


× No keyword cloud information.
  7 in total

1.  Aromatic amino acid decarboxylase deficiency in twins.

Authors:  K Hyland; P T Clayton
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

Review 2.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

3.  Intestinal decarboxylation of L-Dopa in relation to dose requirement in Parkinson's disease.

Authors:  A K Granerus; R Jagenburg; A Svanborg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

4.  Interactions between levodopa and other drugs: significance in the treatment of Parkinson's disease.

Authors:  J R Bianchine; L Sunyapridakul
Journal:  Drugs       Date:  1973       Impact factor: 9.546

Review 5.  Abnormalities of biogenic amine metabolism.

Authors:  K Hyland
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

6.  Absorption, metabolism and distribution of (14C)-O-methyldopa and (14C)-L-dopa after oral administration to rats.

Authors:  L Rivera-Calimlim
Journal:  Br J Pharmacol       Date:  1974-02       Impact factor: 8.739

7.  Catechol-O-methyltransferase inhibition by U-0521 increases striatal utilization of levodopa.

Authors:  A Reches; D Jiang; S Fahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-07       Impact factor: 3.000
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.